UY24735A1 - Procedimiento para la preparacion de antagonistas del receptor de vitronectina.- - Google Patents

Procedimiento para la preparacion de antagonistas del receptor de vitronectina.-

Info

Publication number
UY24735A1
UY24735A1 UY24735A UY24735A UY24735A1 UY 24735 A1 UY24735 A1 UY 24735A1 UY 24735 A UY24735 A UY 24735A UY 24735 A UY24735 A UY 24735A UY 24735 A1 UY24735 A1 UY 24735A1
Authority
UY
Uruguay
Prior art keywords
alkyl
formula
compound
represented
acid
Prior art date
Application number
UY24735A
Other languages
English (en)
Spanish (es)
Inventor
Francis Callahan James
Donovan Cousins Russell
Mccullock Keenan Richard
Chet Kwon
William Miller
Nijole Uzinkas Irene
Original Assignee
Smithkline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Corp filed Critical Smithkline Beecham Corp
Publication of UY24735A1 publication Critical patent/UY24735A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
    • C07D223/14—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D223/16—Benzazepines; Hydrogenated benzazepines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/582—Recycling of unreacted starting or intermediate materials

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Inorganic Chemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
UY24735A 1996-10-02 1997-10-01 Procedimiento para la preparacion de antagonistas del receptor de vitronectina.- UY24735A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US2732096P 1996-10-02 1996-10-02
US4377697P 1997-04-11 1997-04-11

Publications (1)

Publication Number Publication Date
UY24735A1 true UY24735A1 (es) 1998-03-30

Family

ID=26702318

Family Applications (2)

Application Number Title Priority Date Filing Date
UY24735A UY24735A1 (es) 1996-10-02 1997-10-01 Procedimiento para la preparacion de antagonistas del receptor de vitronectina.-
UY24935A UY24935A1 (es) 1996-10-02 1998-03-25 Antagonistas del receptor de vitronectina

Family Applications After (1)

Application Number Title Priority Date Filing Date
UY24935A UY24935A1 (es) 1996-10-02 1998-03-25 Antagonistas del receptor de vitronectina

Country Status (36)

Country Link
EP (1) EP0957917B1 (enExample)
JP (2) JP4491072B2 (enExample)
KR (1) KR100589578B1 (enExample)
CN (1) CN1114403C (enExample)
AP (1) AP1463A (enExample)
AR (1) AR008878A1 (enExample)
AT (1) ATE312089T1 (enExample)
AU (1) AU733417B2 (enExample)
BG (1) BG64581B1 (enExample)
BR (1) BR9712248B1 (enExample)
CA (1) CA2267224C (enExample)
CO (1) CO4900046A1 (enExample)
CY (1) CY2576B1 (enExample)
CZ (1) CZ299076B6 (enExample)
DE (1) DE69734833T2 (enExample)
DK (1) DK0957917T3 (enExample)
DZ (1) DZ2320A1 (enExample)
EA (1) EA002419B1 (enExample)
ES (1) ES2252775T3 (enExample)
HU (1) HU229221B1 (enExample)
ID (1) ID19623A (enExample)
IL (1) IL129243A (enExample)
MA (1) MA24361A1 (enExample)
MY (1) MY137606A (enExample)
NO (1) NO320194B1 (enExample)
NZ (1) NZ334953A (enExample)
PE (1) PE10499A1 (enExample)
PL (1) PL190859B1 (enExample)
RO (1) RO119881B1 (enExample)
SA (1) SA98180936B1 (enExample)
SK (1) SK285029B6 (enExample)
TR (1) TR199900737T2 (enExample)
TW (1) TW487702B (enExample)
UA (1) UA60311C2 (enExample)
UY (2) UY24735A1 (enExample)
WO (1) WO1998014192A1 (enExample)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA60311C2 (uk) * 1996-10-02 2003-10-15 Смітклайн Бічам Корпорейшн Антагоністи рецептора вітронектину, спосіб одержання цих сполук та фармацевтична композиція
TW527355B (en) 1997-07-02 2003-04-11 Bristol Myers Squibb Co Inhibitors of farnesyl protein transferase
IL135189A0 (en) * 1997-09-24 2001-05-20 Smithkline Beecham Corp Vitronectin receptor antagonist
JP2002500162A (ja) * 1997-09-24 2002-01-08 スミスクライン・ビーチャム・コーポレイション ビトロネクチン受容体アンタゴニスト
US6372719B1 (en) * 1998-03-04 2002-04-16 Jay Cunningham ανβ3 integrin antagonists in combination with chemotherapeutic agents
DE19842415A1 (de) 1998-09-16 2000-03-23 Merck Patent Gmbh Pharmazeutische Zubereitung
WO2000038715A2 (en) * 1998-12-23 2000-07-06 G.D. Searle & Co. Use of an integrin antagonist and radiation in the treatment of neoplasia
EP1150965A4 (en) * 1999-02-03 2002-05-15 Merck & Co Inc BENZAZEPINE DERIVATIVES AS ALPHA-V INTGRIN RECEPTOR ANTAGONISTS
MXPA01011052A (es) * 1999-04-30 2002-11-22 Univ Michigan Aplicaciones terapeuticas de benzodiazepinas pro-apoctoticas.
JP2003506452A (ja) * 1999-08-06 2003-02-18 スミスクライン・ビーチャム・コーポレイション 発作の治療に有用なビトロネクチン受容体アンタゴニスト
US6514964B1 (en) 1999-09-27 2003-02-04 Amgen Inc. Fused cycloheptane and fused azacycloheptane compounds and their methods of use
DE10027514A1 (de) * 2000-06-06 2002-01-03 Basf Ag Liganden von Integrinrezeptoren
DE10028575A1 (de) 2000-06-14 2002-03-14 Basf Ag Integrinliganden
FR2806082B1 (fr) * 2000-03-07 2002-05-17 Adir Nouveaux composes bicycliques antagonistes des recepteurs de la vitronectine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
WO2002060438A1 (en) 2001-01-29 2002-08-08 3-Dimensional Pharmaceuticals, Inc. Substituted indoles and their use as integrin antagonists
CN1248692C (zh) * 2001-04-10 2006-04-05 史密丝克莱恩比彻姆公司 玻璃体结合蛋白受体拮抗剂在制备用于抑制粘连形成的药物中的用途
SE0101386D0 (sv) 2001-04-20 2001-04-20 Astrazeneca Ab New compounds
EP1387688A2 (en) * 2001-05-03 2004-02-11 Merck & Co., Inc. Benzazepinone alpha v integrin receptor antagonists
KR20040058229A (ko) 2001-10-22 2004-07-03 더 스크립스 리서치 인스티튜트 항체 표적화 화합물
GB0215867D0 (en) * 2002-07-09 2002-08-14 Glaxosmithkline Spa Novel method and compounds
WO2004089890A2 (en) * 2003-04-04 2004-10-21 Smithkline Beecham Corporation Process and intermediates for preparing benzazepines
EP1734996B1 (en) * 2004-04-02 2013-05-22 The Regents of The University of California Methods and compositions for treating and preventing disease associated with alpha v beta 5 integrin
AU2012216372B2 (en) * 2004-04-02 2015-01-22 The Regents Of The University Of California Methods and compositions for treating and preventing disease associated with alphaVbeta5 integrin
UA87854C2 (en) 2004-06-07 2009-08-25 Мерк Энд Ко., Инк. N-(2-benzyl)-2-phenylbutanamides as androgen receptor modulators
TW200635902A (en) * 2004-12-21 2006-10-16 Smithkline Beecham Corp Methods and formulations
EP1968594B1 (en) * 2005-11-29 2010-09-29 GlaxoSmithKline LLC Treatment of ocular neovascular disorders such as macular degeneration, angiod streaks, uveitis and macular edema
EP2730282A1 (en) 2007-11-08 2014-05-14 The General Hospital Corporation Methods and compositions for the treatment of proteinuric diseases
EP2221308B1 (en) * 2007-11-16 2013-07-10 Ube Industries, Ltd. Benzazepinone compound
US8076475B2 (en) * 2008-03-06 2011-12-13 Glaxosmithkline Llc Process
JP2012517447A (ja) 2009-02-10 2012-08-02 ザ スクリプス リサーチ インスティチュート 化学的にプログラムされたワクチン接種法
EP2415474B1 (en) * 2009-03-30 2013-08-28 Ube Industries, Ltd. Pharmaceutical composition for treatment or prevention of ophthalmic diseases
JP5572996B2 (ja) * 2009-05-15 2014-08-20 宇部興産株式会社 ベンズアゼピノン化合物を有効成分として含有する医薬
JP5755647B2 (ja) 2009-07-24 2015-07-29 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア αvβ5インテグリンに関連する疾患の処置および予防のための方法および組成物
US9126978B2 (en) 2009-11-17 2015-09-08 The Regents Of The University Of Michigan 1,4-benzodiazepine-2,5-diones and related compounds with therapeutic properties
EP2325194A1 (en) * 2009-11-24 2011-05-25 Glycotope GmbH Process for the purification of glycoproteins
ES2864079T3 (es) 2014-05-30 2021-10-13 Pfizer Derivados de carbonitrilo como moduladores selectivos del receptor de andrógenos
BR112022021228A2 (pt) * 2020-04-26 2022-12-06 Jiangsu Nhwa Pharmaceutical Co Ltd Derivado da 1,5-di-hidro-2,4-benzodiazepin-3-ona e aplicação do mesmo
WO2023275715A1 (en) 2021-06-30 2023-01-05 Pfizer Inc. Metabolites of selective androgen receptor modulators

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE236882T1 (de) * 1992-12-21 2003-04-15 Smithkline Beecham Corp Bicyklische fibrinogen antagoniste
ZA955391B (en) * 1994-06-29 1996-02-09 Smithkline Beecham Corp Vitronectin receptor antagonists
WO1996000730A1 (en) * 1994-06-29 1996-01-11 Smithkline Beecham Corporation Vitronectin receptor antagonists
JPH10504825A (ja) * 1994-08-22 1998-05-12 スミスクライン・ビーチャム・コーポレイション 二環式化合物
WO1996026190A1 (en) * 1995-02-22 1996-08-29 Smithkline Beecham Corporation Integrin receptor antagonists
UA60311C2 (uk) * 1996-10-02 2003-10-15 Смітклайн Бічам Корпорейшн Антагоністи рецептора вітронектину, спосіб одержання цих сполук та фармацевтична композиція

Also Published As

Publication number Publication date
JP2010006838A (ja) 2010-01-14
CA2267224A1 (en) 1998-04-09
NO320194B1 (no) 2005-11-14
SK42599A3 (en) 1999-12-10
UA60311C2 (uk) 2003-10-15
CY2576B1 (en) 2008-07-02
SA98180936B1 (ar) 2006-05-30
EA002419B1 (ru) 2002-04-25
AU733417B2 (en) 2001-05-17
JP4491072B2 (ja) 2010-06-30
PL332674A1 (en) 1999-09-27
AU4746297A (en) 1998-04-24
DK0957917T3 (da) 2006-04-18
CN1238689A (zh) 1999-12-15
EA199900356A1 (ru) 2000-02-28
DZ2320A1 (fr) 2002-12-28
EP0957917A4 (en) 2002-05-15
ES2252775T3 (es) 2006-05-16
AP9901493A0 (en) 1999-03-31
CN1114403C (zh) 2003-07-16
TR199900737T2 (xx) 1999-07-21
AP1463A (en) 2005-09-10
CO4900046A1 (es) 2000-03-27
ATE312089T1 (de) 2005-12-15
HU229221B1 (en) 2013-09-30
CZ113299A3 (cs) 2000-03-15
BR9712248A (pt) 1999-08-24
EP0957917B1 (en) 2005-12-07
ID19623A (id) 1998-07-23
MA24361A1 (fr) 1998-07-01
WO1998014192A1 (en) 1998-04-09
IL129243A (en) 2004-07-25
CZ299076B6 (cs) 2008-04-16
KR100589578B1 (ko) 2006-06-15
DE69734833T2 (de) 2006-07-13
AR008878A1 (es) 2000-02-23
JP2001501936A (ja) 2001-02-13
NO991590L (no) 1999-05-31
NO991590D0 (no) 1999-03-31
CA2267224C (en) 2007-03-13
PL190859B1 (pl) 2006-02-28
MY137606A (en) 2009-02-27
BR9712248B1 (pt) 2010-06-29
BG64581B1 (bg) 2005-08-31
HK1023730A1 (en) 2000-09-22
PE10499A1 (es) 1999-03-27
RO119881B1 (ro) 2005-05-30
UY24935A1 (es) 2001-07-31
BG103299A (en) 2000-01-31
IL129243A0 (en) 2000-02-17
DE69734833D1 (de) 2006-01-12
SK285029B6 (sk) 2006-04-06
HUP9903769A2 (hu) 2000-03-28
KR20000048816A (ko) 2000-07-25
TW487702B (en) 2002-05-21
HUP9903769A3 (en) 2000-07-28
EP0957917A1 (en) 1999-11-24
NZ334953A (en) 2000-01-28

Similar Documents

Publication Publication Date Title
Chen et al. Synthesis of the 5-HT1D receptor agonist MK-0462 via a Pd-catalyzed coupling reaction
EP4118071A1 (en) 3-(2-(aminoethyl)-indol-4-ol derivatives, methods of preparation thereof, and the use as 5-ht2 receptor modulators
TW593313B (en) Bicyclic heterocyclic substituted phenyl oxazolidinone antibacterials, and related compositions and methods
US5525624A (en) Non-peptide tachykinin receptor antagonists to treat psycological disorder
CN118108700A (zh) 补体因子b抑制剂及其药物组合物、制备方法和用途
US6995176B2 (en) 1-heterocyclylalkyl-3-sulfonyl-indole or -indazole derivatives as 5-hydroxytryptamine-6 ligands
NO171078B (no) Pumpe
JP3152440B2 (ja) ニューロキニンアンタゴニストとして有用な置換オキシム誘導体
AU2003235259B2 (en) Benzimidazole derivatives
EP0737189B1 (en) Heterocyclic compounds for the treatment of cns and cardiovascular disorders
SE504184C2 (sv) Användning av vissa 3-HT3-antagonister för framställning av läkemedel
WO2002066478A1 (en) Antagonists of gonadotropin releasing hormone
JP2004517072A (ja) Cns障害の治療において有用な化合物
NO162977B (no) Filt for fremstilling av en vaatpressefilt for en papirmaskin, samt fremgangsmaate ved fremstilling derav.
PL98220B1 (pl) Sposob wytwarzania nowych pochodnych benzimidazolinonu
MX9605838A (es) Cierre de anillo de triazoliltriptamina catalizado con paladio.
EP2736906B1 (en) N-(IMIDAZOLIDIN-2-YLIDENE)-HETEROCYCLOPENTA[b]PYRIDINE DERIVATIVES AS MODULATORS OF ALPHA 2 ADRENERGIC RECEPTORS
KR970001347A (ko) 벤즈이소티아졸릴 치환 아미노메틸크로만
IE902788A1 (en) 2,3-Dihydro-1-(pyridinylamino)-indoles, a process for their preparation and their use as medicaments
Heinzelman et al. Recent studies in the field of indole compounds
JP2902484B2 (ja) 5ht1−様作動薬としてのインドール誘導体
JP2001526674A (ja) 5ht2c受容体アンタゴニストとしてのインドリン誘導体
TWI311557B (en) Pharmaceutically active diazepanes
HU211701A9 (en) Hydroxy-1,2,3,4-tetrahydroaminoacridines, a process for their preparation and their use as medicaments
NO123894B (enExample)

Legal Events

Date Code Title Description
VENC Patent expired

Effective date: 20171001